These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 7782050)
1. Auditory brainstem responses in thyroid diseases before and after therapy. Di Lorenzo L; Foggia L; Panza N; Calabrese MR; Motta G; Tranchino G; Orio F; Lombardi G Horm Res; 1995; 43(5):200-5. PubMed ID: 7782050 [TBL] [Abstract][Full Text] [Related]
2. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562 [TBL] [Abstract][Full Text] [Related]
3. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease. Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159 [TBL] [Abstract][Full Text] [Related]
9. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease. Choo YK; Yoo WS; Kim DW; Chung HK Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556 [TBL] [Abstract][Full Text] [Related]
10. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414 [TBL] [Abstract][Full Text] [Related]
11. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084 [TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis. Kojima N; Sakata S; Nakamura S; Nagai K; Takuno H; Ogawa T; Matsui I; Sarui H; Miura K J Endocrinol Invest; 1992; 15(7):491-6. PubMed ID: 1447487 [TBL] [Abstract][Full Text] [Related]
13. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093 [TBL] [Abstract][Full Text] [Related]
14. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders. Bartalena L; Martino E; Falcone M; Buratti L; Grasso L; Mammoli C; Pacchiarotti A; Aghini-Lombardi F; Balzano S; Pinchera A J Clin Endocrinol Metab; 1987 Dec; 65(6):1265-71. PubMed ID: 3680483 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves' disease. Wan Nazaimoon WM; Khalid BA Horm Metab Res; 1998 Apr; 30(4):213-6. PubMed ID: 9623636 [TBL] [Abstract][Full Text] [Related]
17. Comparison between TRH-stimulated TSH and basal TSH measurement by a commercial immunoradiometric assay in the management of thyroid disease. De Rosa G; Testa A; Giacomini D; Carrozza C; Maussier ML; Valenza V; D'Errico GF Q J Nucl Med; 1996 Jun; 40(2):182-7. PubMed ID: 8909104 [TBL] [Abstract][Full Text] [Related]
18. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Ozkaya M; Sahin M; Cakal E; Yuzbasioglu F; Sezer K; Kilinc M; Imrek SS J Endocrinol Invest; 2009 May; 32(5):435-9. PubMed ID: 19498324 [TBL] [Abstract][Full Text] [Related]
19. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease. Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880 [TBL] [Abstract][Full Text] [Related]